BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 16214255)

  • 21. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
    Hollander PA; Schwartz SL; Gatlin MR; Haas SJ; Zheng H; Foley JE; Dunning BE
    Diabetes Care; 2001 Jun; 24(6):983-8. PubMed ID: 11375357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial effects of nateglinide on insulin resistance in type 2 diabetes.
    Hazama Y; Matsuhisa M; Ohtoshi K; Gorogawa S; Kato K; Kawamori D; Yoshiuchi K; Nakamura Y; Shiraiwa T; Kaneto H; Yamasaki Y; Hori M
    Diabetes Res Clin Pract; 2006 Mar; 71(3):251-5. PubMed ID: 16214255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of nateglinide in impaired glucose tolerance subjects].
    Hirose T
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():438-43. PubMed ID: 15779419
    [No Abstract]   [Full Text] [Related]  

  • 24. [Nateglinide].
    Notoya Y; Kikuchi M
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():371-5. PubMed ID: 12387020
    [No Abstract]   [Full Text] [Related]  

  • 25. Restoring post-prandial insulin release in type 2 diabetes.
    Andrews J
    Hosp Med; 2002 Feb; 63(2):95-8. PubMed ID: 11902096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of nateglinide in the management of patients with type 2 diabetes.
    Tentolouris N; Voulgari C; Katsilambros N
    Vasc Health Risk Manag; 2007; 3(6):797-807. PubMed ID: 18200800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes].
    Ikenoue T; Kondo N
    Nihon Yakurigaku Zasshi; 2000 Sep; 116(3):171-80. PubMed ID: 11031747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Significance of insulin secretion pattern lectured by "glinides" in the treatment of postprandial hyperglycemia].
    Hirose T
    Nihon Rinsho; 2005 Dec; 63(12):2237-44. PubMed ID: 16363700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Nateglinide and mitiglinide].
    Odawara M
    Nihon Rinsho; 2003 Jul; 61(7):1230-7. PubMed ID: 12877090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diabetes prevention: can insulin secretagogues do the job?
    Westerhaus B; Gosmanov AR; Umpierrez GE
    Prim Care Diabetes; 2011 Jul; 5(2):73-80. PubMed ID: 21185798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
    Yamada K
    Nihon Rinsho; 2003 Jul; 61(7):1219-23. PubMed ID: 12877088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Preclinical studies of AY4166 (A-4166)].
    Kondo N
    Nihon Rinsho; 1997 Nov; 55 Suppl():159-63. PubMed ID: 9434461
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
    McLeod JF
    Clin Pharmacokinet; 2004; 43(2):97-120. PubMed ID: 14748619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control.
    Pratley RE; Foley JE; Dunning BE
    Curr Pharm Des; 2001 Sep; 7(14):1375-97. PubMed ID: 11472274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
    Kikuchi M
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Glinide(s), sulfonylurea(s)].
    Arakawa M; Hirose T
    Nihon Rinsho; 2006 Nov; 64(11):2107-12. PubMed ID: 17087304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes.
    Israel MK; Istvan E; Baron MA
    Vasc Health Risk Manag; 2008; 4(6):1167-78. PubMed ID: 19337530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quo vadis nateglinide? Ten-year perspective.
    Grunberger G
    Expert Opin Pharmacother; 2011 Sep; 12(13):2097-106. PubMed ID: 21801074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapies for newly-onset diabetic patients].
    Kawamori R
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():525-32. PubMed ID: 15779435
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.